deltatrials
Completed PHASE2 NCT00209989

Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Phase I/II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Sponsor: Institut Claudius Regaud

Conditions Glioblastoma Multiforme
Interventions Zarnestra standard Radiation therapy
Updated 6 times since 2017 Last updated: Nov 23, 2011 Started: Oct 31, 2005 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

A PHASE2 clinical study on Glioblastoma Multiforme, this trial is completed. The trial is conducted by Institut Claudius Regaud and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut Claudius Regaud
  • Janssen-Cilag Ltd.
Data source: Institut Claudius Regaud

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Clermont-Ferrand, France
  • • Toulouse, France